logo-loader
viewMaxCyte Inc

MaxCyte offering exposure to 'explosive growth' in cell therapy and cellular engineering

Proactive Research analyst Emma Ulker gives her view on the work MaxCyte Inc's (LON:MXCT) doing in the area of cell and gene therapy.

MXCT has more than 80 licensed programmes including more than 45 licensed for clinical use.

They've announced seven clinical/commercial partnership deals with leading names in the field of cell and gene therapy.

Ulker adds that the field is experiencing a huge step up in investment - rising by more than 77% year-on-year in 2018. 

Click here to read Emma Ulker's latest research note on MaxCyte

Quick facts: MaxCyte Inc

Price: 294 GBX

AIM:MXCT
Market: AIM
Market Cap: £217.59 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc 'demonstrating outstanding progress' as first half revenues...

Proactive Research analyst Emma Ulker discusses MaxCyte Inc's (LON:MXCT) first half trading update in which it revealed revenues grew by 30% to US$10.9mln and that its research and development operation's expected to be self-funded by the end of the year. Ulker says trading reflected the solid...

3 weeks ago

2 min read